{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:06:51Z","timestamp":1776938811679,"version":"3.51.4"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Immunomodulatory drugs including thalidomide, lenalidomide (<jats:styled-content style=\"fixed-case\">LEN<\/jats:styled-content>) and pomalidomide (<jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content>), are effective for treating multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content> has shown enhanced efficacy with dexamethasone (<jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content>). Pegylated liposomal doxorubicin (<jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content>) with bortezomib is <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> Food and Drug Administration\u2010approved for treating <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">LEN<\/jats:styled-content> or thalidomide has shown efficacy for <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> patients. <jats:styled-content style=\"fixed-case\">LEN<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PLD<\/jats:styled-content> and bortezomib achieves high response rates. We evaluated the combination of <jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> 40\u00a0mg and <jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content> 5\u00a0mg\/m<jats:sup>2<\/jats:sup> with the latter two drugs administered on days 1, 4, 8 and 11 on a 28\u2010day cycle for the treatment of relapsed\/refractory <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> patients. During Phase 1, the maximum tolerated dose of <jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content> was 4\u00a0mg, and was used in Phase 2, which also required patients to be refractory to <jats:styled-content style=\"fixed-case\">LEN<\/jats:styled-content>. However, neutropenia \u2265 grade 3 was observed in 10\/17 (59%) patients, and the dose was lowered to 3\u00a0mg. Median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 5\u00b74\u00a0months (range, 0\u00b73\u201329\u00b70\u00a0+\u00a0 months). Overall response rates for patients in Phase 2 were 39% and 31% among subjects receiving <jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content> at 3\u00a0mg and 4\u00a0mg, respectively, and clinical benefit rates were 51% and 44%, respectively. <jats:styled-content style=\"fixed-case\">POM<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PLD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DEX<\/jats:styled-content> is a treatment option for relapsed\/refractory <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> patients including those who are refractory to <jats:styled-content style=\"fixed-case\">LEN<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14992","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T03:32:44Z","timestamp":1511321564000},"page":"60-70","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma"],"prefix":"10.1111","volume":"180","author":[{"given":"Alexa","family":"Cohen","sequence":"first","affiliation":[{"name":"Oncotherapeutics West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Spektor","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Stampleman","sequence":"additional","affiliation":[{"name":"Pacific Cancer Care Monterey CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bessudo","sequence":"additional","affiliation":[{"name":"California Cancer Associates for Research and Excellence San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Providence Saint Joseph Medical Center Burbank CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard M.","family":"Klein","sequence":"additional","affiliation":[{"name":"Illinois Cancer Specialists Niles IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Woliver","sequence":"additional","affiliation":[{"name":"Cancer Center of Santa Barbara Santa Barbara CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall","family":"Flam","sequence":"additional","affiliation":[{"name":"Hematology\u2010Oncology Medical Group Fresno CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[{"name":"James R. Berenson, MD, Inc West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youram","family":"Nassir","sequence":"additional","affiliation":[{"name":"Cancer Care Institute Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Maluso","sequence":"additional","affiliation":[{"name":"James R. Berenson, MD, Inc West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina A.","family":"Swift","sequence":"additional","affiliation":[{"name":"James R. Berenson, MD, Inc West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[{"name":"Oncotherapeutics West Hollywood CA USA"},{"name":"James R. Berenson, MD, Inc West Hollywood CA USA"},{"name":"Institute for Myeloma and Bone Cancer Research West Hollywood CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl313"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08884.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.51"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/blood.V128.22.4516.4516","article-title":"Daratumumab single agent and daratumumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a real life retrospective evaluation","volume":"128","author":"Branca A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.V128.22.1145.1145","article-title":"A multicenter, open label phase I\/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma (MM) patients","volume":"128","author":"Bringhen S.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_7_1","first-page":"1409","article-title":"LAG\u03bb\u20101: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma","volume":"28","author":"Campbell R.A.","year":"2006","journal-title":"International Journal of Oncology"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109470"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700872"},{"key":"e_1_2_7_11_1","first-page":"300","article-title":"Staging and kinetics of multiple myeloma","volume":"13","author":"Durie B.G.","year":"1986","journal-title":"Seminars in Oncology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/blood.V128.22.3337.3337","article-title":"Efficacy of carfilzomib (K), pomalidomide (P), and dexamethasone (d) in heavily pretreated patients with relapsed\/refractory multiple myeloma (RRMM) in a real world setting","volume":"128","author":"Hobbs M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.889"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood.V128.22.3316.3316","article-title":"A phase I\/II trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in relapsed\/refractory (R\/R) multiple myeloma (MM) patients: responses in double\/triple refractory myeloma and poor risk cytogenetics","volume":"128","author":"Krishnan A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6802"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.190"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348896"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14263"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.11.009"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V128.22.3307.3307","article-title":"Selective HDAC6 Inhibitor ACY\u2010241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed\u2010and\u2010Refractory Multiple Myeloma","volume":"128","author":"Niesvizky R.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"e0173507","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti\u2010tumor response with ACY\u2010241, a selective HDAC6 inhibitor","volume":"12","author":"North B.J.","year":"2017","journal-title":"PLoS"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.238"},{"key":"e_1_2_7_25_1","first-page":"133","article-title":"Low\u2010dose thalidomide with pegylated liposomal doxorubicin and high\u2010dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani M.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013086"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.07.007"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-450742"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.02.001"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13905"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.125864"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.052"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1177181"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07013.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T19:37:28Z","timestamp":1696016248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.14992"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14992","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"assertion":[{"value":"2017-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}